{ "schema": "OTR-SIGNALS-CATEGORY-EDITION-1", "release_id": "OTR-SIGNALS-20261009T171430Z-R1", "parent_edition_release_id": "OTR-2026-10-08-0100-SGT-R1", "parent_full_edition": { "release_id": "OTR-2026-10-08-0100-SGT-R1", "path": "/data/edition/current.json", "sha256": "68ab60331b3133c5fa8898894fdc1addc9b66cde49bf14aed50289f3e1fcc616" }, "source_handoff": { "schema": "OTR-SIGNALS-PUBLISHER-ASSEMBLY-1", "publisher_stage_sha256": "cd7fa0e617e31c8ccb0ea64417cf8792d21cad74fefbe4d7ab3c5f94d01eb253", "parent_signals_release_id": "OTR-SIGNALS-20261009T142200Z-R1", "parent_full_edition": { "release_id": "OTR-2026-10-08-0100-SGT-R1", "path": "/data/edition/current.json", "sha256": "68ab60331b3133c5fa8898894fdc1addc9b66cde49bf14aed50289f3e1fcc616" }, "research_start_utc": "2026-10-09T16:44:30Z", "research_cutoff_utc": "2026-10-09T17:14:30Z", "evidence_lookback_start_utc": "2026-10-08T17:14:30Z", "actual_research_duration_minutes": 30, "noninvestment_projection_sha256": "54d5d236a24e8addee66774575805b28129b0621584ad45245c13cb5fe99bba5", "noninvestment_projection_review_sha256": "d25b1689ebc2442522e53d9376ae452503ee011fce626a27eb7674f15b6dee95", "final_investment_approval_batch_sha256": "0f59e7c73ab876aeff96fba4bb17629cfbadec06bb9c23e9241a8bdaf1e0eaf8", "final_privacy_projection_guard_approval_sha256": "0894ec31431b0bca3562e55d00d215cd55f863e75a6d5fa92066de0e701a39fd", "final_arrival_check_sha256": "fccfc110230f59033f9984d06e25a013a1cb9fb8531ae12c5a0fb7bf4d639b28", "combined_bounded_read_manifest_sha256": "8e056567bcdd4a90321dfba2a49ee5212ad6999af97c53c94cf089dcc3e4b0b7", "preservation_baseline_sha256": "ac49613aefda1b4f2396f6a0a1a00f2c760ca8288269f9bb3435222d7ddb98b4", "current_parent_observation_sha256": "17cb983b2f3394ad2202f5f630aa50488aa5cea68315ee4c06b1f7faa3435dbf", "noninvestment_records": [ { "id": "GEN-20261009-AI-TRADE-LOCAL-INCOME-TRANSMISSION", "category": "general", "candidate_sha256": "c56a112a16e16cf2eac6c3ca6998d33b8a6d0f81f603e23bf54f4335a3853b13", "projected_record_sha256": "e0831ba41a34926069b452cd59ae1ec4316538569cc859df85a71571b4159634", "public_record_sha256": "e0831ba41a34926069b452cd59ae1ec4316538569cc859df85a71571b4159634", "review_receipt_sha256": "485b852c1de08b8c060a1f1b720a926ebb492895474ac4397e7046dd9a52ece0", "privacy_redactions": [] }, { "id": "GEN-20261009-MEDICARE-CHOICE-PAYMENT-CLOCKS", "category": "general", "candidate_sha256": "ca5f4d0f501dec0caa0fac00f74f6f6267a8c0ed33778aefe452e08c9d48e68d", "projected_record_sha256": "f76d621c7ac571768bcc83bec13efd5152255d4403341fe31eb584091683a12d", "public_record_sha256": "f76d621c7ac571768bcc83bec13efd5152255d4403341fe31eb584091683a12d", "review_receipt_sha256": "ec50f255529145f31b9b5ab4096690f34d5b661caf97053ced469670e153f24e", "privacy_redactions": [] }, { "id": "SG-20261009-BIOLNG-CERTIFIED-DELIVERY-GATES", "category": "singapore", "candidate_sha256": "11d88f6f77179b5516578dcab24d3c245b637f2b0a539b6ebda236fd44ca487b", "projected_record_sha256": "d8950ad6d344921159849483fcea815ca05a47ce196be3e56089d19b51e8fb85", "public_record_sha256": "d8950ad6d344921159849483fcea815ca05a47ce196be3e56089d19b51e8fb85", "review_receipt_sha256": "b84d626a78fc0069bb617efdbc7a841e0a9f89e03f111d405af5e09bd9cf31b7", "privacy_redactions": [] }, { "id": "SG-20261009-ENEOS-LUBRICANT-BUYER-ALTERNATIVES", "category": "singapore", "candidate_sha256": "1533fe44c9fa1d606cfd5c51528c034997d4462235c2989f398a059fbb3769d1", "projected_record_sha256": "550889f1f3183bb114b3a084830a8e89206f8573bc19290bd1a1ae18180a790f", "public_record_sha256": "550889f1f3183bb114b3a084830a8e89206f8573bc19290bd1a1ae18180a790f", "review_receipt_sha256": "0cb18195396a6e926cb04517261c3d29e5f30e9b1673b4ba6acc40f2d3a6bc34", "privacy_redactions": [] }, { "id": "SOC-20261009-BYLINE-DISCUSSION-DISTRIBUTION-UNIT", "category": "social", "candidate_sha256": "6cfc54076fc73f26dd81eb5975c0ab22c6f8f32bb429b85c5e232849ffae4a0a", "projected_record_sha256": "7eb42c0164903173a38c12bc89a701ea6eff68bd3d6c4af03308bc897ca9ab47", "public_record_sha256": "7eb42c0164903173a38c12bc89a701ea6eff68bd3d6c4af03308bc897ca9ab47", "review_receipt_sha256": "4baad0ce5437dc4e6a996355f18c7bc1dfd186941c0531eae32e9415839c5169", "privacy_redactions": [] }, { "id": "SOC-20261009-MEETING-FOCUS-AUTHORITY-TRADEOFF", "category": "social", "candidate_sha256": "26fc034f2766f38751839aae8c61d9e94728dcb2c2d8e1865265dd5cac157308", "projected_record_sha256": "7c5f5694c76162e9ad39b9452f8a98a1d0940f98744b0a4ddbff49f13897ffe8", "public_record_sha256": "7c5f5694c76162e9ad39b9452f8a98a1d0940f98744b0a4ddbff49f13897ffe8", "review_receipt_sha256": "91321409254939fa56f41445f630b8f3aa54c1acd491c0e7b58fb918fe60c5f0", "privacy_redactions": [] }, { "id": "TECH-20261009-MULTILINGUAL-TOKEN-EVIDENCE-BUDGET", "category": "technology", "candidate_sha256": "b938f135fe8e12587761864630f0ea24812ca7e13b95f5307aa7b4cf6107a3f4", "projected_record_sha256": "7c555a0c5c4964d69baaf5087b3af8dc486e67c047cbd07ccc44600da27cbbfb", "public_record_sha256": "7c555a0c5c4964d69baaf5087b3af8dc486e67c047cbd07ccc44600da27cbbfb", "review_receipt_sha256": "5c51c53bce5a982500834d2299ea77273c1e6d83e5143443ddce77ae27f97bbf", "privacy_redactions": [] }, { "id": "TECH-20261009-HYBRID-NETWORK-PATH-CAPACITY", "category": "technology", "candidate_sha256": "5cdea8f780e035c79bb628e28b2e47c23b702b3433499514fc534409073bac70", "projected_record_sha256": "55873f77c4d663f79e4bda756dc4d347bdc996ae8018a211a5764bd1db3b2e5a", "public_record_sha256": "55873f77c4d663f79e4bda756dc4d347bdc996ae8018a211a5764bd1db3b2e5a", "review_receipt_sha256": "cc8d0ac8e85de1544f185e38d7cebd1000433c48de4c5ce978ba0bf77a892067", "privacy_redactions": [] } ], "investment_artifacts": [ { "schema": "OTR-SIGNALS-CURRENT-RUN-INVESTMENT-ARTIFACT-1", "release_id": "OTR-SIGNALS-20261009T171430Z-R1", "signal_id": "INV-20261009-HUMANA-RATINGS-REPAIR-168H", "call_id": "SCALL-9f1bd6ca2b7b6e5e62771889", "public_card_sha256": "f43b41844989868f939c7c33d8b218066112ba3978ca6134dbd88954b12fe672", "freeze_receipt_sha256": "a52c4b3cc83a185f0aac4c0925471be809e2567508c48420fcab10578b028360", "frozen_at_utc": "2026-10-09T17:25:42.687Z", "final_review_status": "PASS", "final_review_sha256": "5f1ea12ca1d9ce11a7723ed87a34dc6edea9dbf7d891026a4f03666a3623b29f", "issue_utc": "2026-10-09T17:25:42.687Z", "expiry_utc": "2026-10-16T17:25:42.687Z", "horizon_hours": 168, "source_evidence_paths": { "frozen_card": "docs/automation/research/OTR-SIGNALS-20261009T171430Z-R1/source-archive/inputs/investment/hum_card_FROZEN.original.json", "public_card": "docs/automation/research/OTR-SIGNALS-20261009T171430Z-R1/publisher-staging/final-investment-cards/hum_card_PUBLIC_NORMALIZED.json", "freeze_receipt": "docs/automation/research/OTR-SIGNALS-20261009T171430Z-R1/source-archive/inputs/investment/hum_freeze_receipt.json", "final_review": "docs/automation/research/OTR-SIGNALS-20261009T171430Z-R1/source-archive/inputs/review/hum-final-approval.json" }, "original_frozen_card_file_sha256": "f13f2ee2dbaa5a6abf647651b361bdff6e7d4091af3670c74b459a92f07ca51f", "original_frozen_card_canonical_sha256": "7dfcc99626993711d03c36e14a2e68bfed25aafb9636ecfe6d611a1e1b29994b", "reference_quote": { "price": 435.53, "symbol": "HUM", "instrument": "Humana Inc. common stock", "currency": "USD", "unit": "USD per common share", "venue": "NYSE-listed / CBOE-attributed StockAnalysis last-price display", "source_url": "https://stockanalysis.com/stocks/hum/", "price_type": "PROVIDER_LAST_SALE_DISPLAY", "provider": "StockAnalysis CBOE-attributed display", "source_clock_display": "Oct 9, 2026, 1:24 PM EDT", "source_clock_utc": "2026-10-09T17:24:00.000Z", "source_clock_interval_utc": [ "2026-10-09T17:24:00.000Z", "2026-10-09T17:24:59.999Z" ], "source_clock_precision_seconds": 60, "source_clock_basis": "Displayed EDT provider price-update minute; converted using America/New_York. Minute start is a conservative age proxy, not an exact trade time.", "retrieved_at_utc": "2026-10-09T17:25:33.304Z", "raw_receipt_sha256": "ae4ecf2444bf90a412579fab682a0cc156df38d90b7a02ddbc1d9e1f9281417b", "observation_time_verified": true, "executed_trade_verified": false, "quote_age_at_issue_seconds": 102.687992 }, "outcome_contract": { "directional_rule": "sign_only", "endpoint_selection": "nearest_legitimate_source_timed_indicative_observation", "provider_change_policy": "allow_if_predeclared_and_disclosed", "allowed_providers": [ "StockAnalysis CBOE-attributed display", "Yahoo Finance exchange-attributed quote", "Nasdaq public quote", "NYSE public quote" ], "same_instrument_and_currency_required": true, "missing_endpoint": "UNVERIFIABLE", "neutral_band_affects_directional_result": false, "regular_session_only": true, "tie_break": "earlier_observation", "price_conventions_allowed": [ "source-timed displayed last price", "explicitly indicative share-price estimate" ], "disclose_actual_endpoint_provider_and_convention": true, "eligible_observation_kinds": [ "source_timed_quote", "explicitly_labeled_timestamped_bar" ], "timestamped_bar_requires_source_field_interval_and_label": true, "no_undated_daily_or_current_widget_substitute": true, "allowed_price_conventions": [ "PROVIDER_LAST_SALE_DISPLAY", "EXCHANGE_ATTRIBUTED_LAST_PRICE", "EXPLICITLY_INDICATIVE_SHARE_PRICE", "TIMESTAMPED_BAR_CLOSE" ], "convention_change_policy": "allow_if_predeclared_and_disclosed", "convention_change_disclosure_required": true, "rule": "FROZEN CONTRACT: Humana Inc. common stock, HUM, USD per share. Entry uses the main StockAnalysis real-time price display attributed to CBOE, an indicative provider display rather than a verified primary-exchange execution or user fill. Freeze only in the regular US equity session when the displayed full-date source minute starts no more than 120 seconds before actual issue. Preserve the source-minute uncertainty interval and retrieval time. Expiry is actual issue plus 168 elapsed hours, expected in the 16 October 2026 regular session, 09:30–16:00 EDT (13:30–20:00 UTC). Resolve using the nearest legitimate retained source-timed indicative observation for the same common share and USD currency in that regular session; earlier observation wins an equal-distance tie. The predeclared permitted sources are StockAnalysis’s CBOE-attributed display, Yahoo Finance’s exchange-attributed quote, or the public Nasdaq or NYSE quote. Provider or price-convention changes among these are allowed only when the actual provider, convention, observation precision, retrieval time and signed source-minus-deadline offset are disclosed. A source-timed displayed last price or explicitly indicative share-price estimate is eligible; it is not a promised execution. An explicitly labeled source-timed bar observation is also eligible if its source field, full interval and price convention are retained; it is a bar observation, not an execution at the deadline. Provider and convention changes are predeclared and must be disclosed. No undated daily figure, unstamped current widget or extended-session substitute is allowed. If no legitimate comparable dated endpoint is retained, mark UNVERIFIABLE. BULLISH is HIT only when P1>P0; flat or the opposite sign is MISS. The inclusive ±2% scenario band is separate and never changes directional scoring. Fees, spreads, taxes, financing and dividends are excluded. Publication never restarts the frozen clock. Frozen issue: 2026-10-09T17:25:42.687Z; exact expiry: 2026-10-16T17:25:42.687Z; reference: USD 435.53 per share, source minute 2026-10-09T17:24:00.000Z.", "disclosure_required": true, "provider_change_disclosure_required": true }, "probability_call_sha256": "026776c7bbdc7f7b090641bf716ae9766e60c2097df8207695759ebb327e14be", "probability_record_path": "docs/automation/research/OTR-SIGNALS-20261009T171430Z-R1/publisher-staging/probability-bindings/SCALL-9f1bd6ca2b7b6e5e62771889.json", "probability_record_sha256": "12424c63ffd6f86ef3faccfbef4efc0a89b6142c95d67316ccc1c558b05fda56", "research_artifact_path": "private/operational-receipts/probability/SCALL-9f1bd6ca2b7b6e5e62771889/research.json", "research_artifact_sha256": "c82f8ff142b3c51d449903871d532d60fc3123e4b64d5dc6e0989eeba9b0d4dd" }, { "schema": "OTR-SIGNALS-CURRENT-RUN-INVESTMENT-ARTIFACT-1", "release_id": "OTR-SIGNALS-20261009T171430Z-R1", "signal_id": "INV-20261009-PEP-MARGIN-RESET-168H", "call_id": "SCALL-6b7a81fad29027f1611c5be6", "public_card_sha256": "ca19a769cca8e3a1073e98e3de979076e09105bfefc05e285f443550773cf148", "freeze_receipt_sha256": "8e487e49e2b5630eb89c66f4d618afba4b7eec34c4179803183738cb38b4c8b7", "frozen_at_utc": "2026-10-09T17:25:55.177Z", "final_review_status": "PASS", "final_review_sha256": "1560b00935f445cc90886e30dfd4fc5e1251c0ecaed13d5d54aea764e2e38c7c", "issue_utc": "2026-10-09T17:25:55.177Z", "expiry_utc": "2026-10-16T17:25:55.177Z", "horizon_hours": 168, "source_evidence_paths": { "frozen_card": "docs/automation/research/OTR-SIGNALS-20261009T171430Z-R1/source-archive/inputs/investment/pep_card_FROZEN.original.json", "public_card": "docs/automation/research/OTR-SIGNALS-20261009T171430Z-R1/publisher-staging/final-investment-cards/pep_card_PUBLIC_NORMALIZED.json", "freeze_receipt": "docs/automation/research/OTR-SIGNALS-20261009T171430Z-R1/source-archive/inputs/investment/pep_freeze_receipt.json", "final_review": "docs/automation/research/OTR-SIGNALS-20261009T171430Z-R1/source-archive/inputs/review/pep-final-approval.json" }, "original_frozen_card_file_sha256": "240df668d07281611c2f9426c1ecbd2155f13186901deebad12ac791870810dc", "original_frozen_card_canonical_sha256": "4a36103181707d71e511ea3fad771991b2d120884be9603d90a4169251af1b51", "reference_quote": { "price": 126.21, "symbol": "PEP", "instrument": "PepsiCo, Inc. common stock", "currency": "USD", "unit": "USD per common share", "venue": "NASDAQ-listed / CBOE-attributed StockAnalysis last-price display", "source_url": "https://stockanalysis.com/stocks/pep/", "price_type": "PROVIDER_LAST_SALE_DISPLAY", "provider": "StockAnalysis CBOE-attributed display", "source_clock_display": "Oct 9, 2026, 1:24 PM EDT", "source_clock_utc": "2026-10-09T17:24:00.000Z", "source_clock_interval_utc": [ "2026-10-09T17:24:00.000Z", "2026-10-09T17:24:59.999Z" ], "source_clock_precision_seconds": 60, "source_clock_basis": "Displayed EDT provider price-update minute; converted using America/New_York. Minute start is a conservative age proxy, not an exact trade time.", "retrieved_at_utc": "2026-10-09T17:25:46.935Z", "raw_receipt_sha256": "105c5c8b1bc41de5a11fb35c833ba5a0701448afd1c081a1a49f23713bb29f16", "observation_time_verified": true, "executed_trade_verified": false, "quote_age_at_issue_seconds": 115.177109 }, "outcome_contract": { "directional_rule": "sign_only", "endpoint_selection": "nearest_legitimate_source_timed_indicative_observation", "provider_change_policy": "allow_if_predeclared_and_disclosed", "allowed_providers": [ "StockAnalysis CBOE-attributed display", "Yahoo Finance exchange-attributed quote", "Nasdaq public quote", "NYSE public quote" ], "same_instrument_and_currency_required": true, "missing_endpoint": "UNVERIFIABLE", "neutral_band_affects_directional_result": false, "regular_session_only": true, "tie_break": "earlier_observation", "price_conventions_allowed": [ "source-timed displayed last price", "explicitly indicative share-price estimate" ], "disclose_actual_endpoint_provider_and_convention": true, "eligible_observation_kinds": [ "source_timed_quote", "explicitly_labeled_timestamped_bar" ], "timestamped_bar_requires_source_field_interval_and_label": true, "no_undated_daily_or_current_widget_substitute": true, "allowed_price_conventions": [ "PROVIDER_LAST_SALE_DISPLAY", "EXCHANGE_ATTRIBUTED_LAST_PRICE", "EXPLICITLY_INDICATIVE_SHARE_PRICE", "TIMESTAMPED_BAR_CLOSE" ], "convention_change_policy": "allow_if_predeclared_and_disclosed", "convention_change_disclosure_required": true, "rule": "FROZEN CONTRACT: PepsiCo, Inc. common stock, PEP, USD per share. Entry uses the main StockAnalysis real-time price display attributed to CBOE, an indicative provider display rather than a verified primary-exchange execution or user fill. Freeze only in the regular US equity session when the displayed full-date source minute starts no more than 120 seconds before actual issue. Preserve the source-minute uncertainty interval and retrieval time. Expiry is actual issue plus 168 elapsed hours, expected in the 16 October 2026 regular session, 09:30–16:00 EDT (13:30–20:00 UTC). Resolve using the nearest legitimate retained source-timed indicative observation for the same common share and USD currency in that regular session; earlier observation wins an equal-distance tie. The predeclared permitted sources are StockAnalysis’s CBOE-attributed display, Yahoo Finance’s exchange-attributed quote, or the public Nasdaq or NYSE quote. Provider or price-convention changes among these are allowed only when the actual provider, convention, observation precision, retrieval time and signed source-minus-deadline offset are disclosed. A source-timed displayed last price or explicitly indicative share-price estimate is eligible; it is not a promised execution. An explicitly labeled source-timed bar observation is also eligible if its source field, full interval and price convention are retained; it is a bar observation, not an execution at the deadline. Provider and convention changes are predeclared and must be disclosed. No undated daily figure, unstamped current widget or extended-session substitute is allowed. If no legitimate comparable dated endpoint is retained, mark UNVERIFIABLE. BEARISH is HIT only when P1+2%; bearish means R<−2%; neutral means −2%≤R≤+2%. These are mutually exclusive and exhaustive when a valid matching endpoint exists. A missing or mismatched quote is UNVERIFIABLE, never neutral. The separate BULLISH direction scores HIT only for P1>P0 and MISS for P1≤P0. Thus a small rise may be both a neutral-band outcome and a directional HIT. Adding to 100 does not establish calibration or tradable profit.", "rationale": "We start from the competing explanations: further recognition of a repaired earnings path, complete pricing of the news, or a fade after a very large opening gap. The company-specific ratings and official bonus timetable support the first; unchanged current-year guidance, the one-time element and observed retreat support the others. Our 52/30/18 judgment weighs all of them. We did not fit likelihood ratios, infer a posterior from the 49 bars, or borrow OTR’s historical hit rate. This is an explicit subjective estimate with no calibrated confidence interval. A fresh price break or new issuer information requires review before issue, rather than a mechanical copy of this draft.", "againstThisView": "The largest objection is price: most of the initial gain happened before any OTR call, and the share then fell from its opening level. A large event can finish repricing immediately. The filing also says some bonus-year outperformance will be one-time and may fund one-time investment and shareholder returns. It reaffirms 2026 adjusted EPS of at least $9 rather than raising it. The company’s normalized bonus comparison is not an actual 2028 revenue forecast; membership, contract mix, risk scores and payment conditions can change. We therefore reject both “95% of members means 95% earnings growth” and treating the whole future benefit as recurring. Next week’s enrollment opening is a public milestone, not a promised new earnings announcement. [Filing and limitations](https://www.sec.gov/Archives/edgar/data/49071/000004907126000057/hum-20261009.htm)", "whatChangesIt": "Before issue, a renewed break below the observed $428.45 session low would require us to reconsider whether buyers are retaining the new rating information. After issue, continued prices below that level or a verified adverse change to the ratings or earnings explanation would weaken the bullish reasoning. Recovery above the $450.49 opening would support the price side, but neither price test proves the business cause. We also weaken the view if enrollment disclosures or an issuer update contradict the assumed benefit. These are review conditions, not stop orders. They cannot change a frozen reference, probabilities, deadline or outcome rule. The one-week outcome remains a same-instrument source-timed price test.", "resolutionRule": "FROZEN CONTRACT: Humana Inc. common stock, HUM, USD per share. Entry uses the main StockAnalysis real-time price display attributed to CBOE, an indicative provider display rather than a verified primary-exchange execution or user fill. Freeze only in the regular US equity session when the displayed full-date source minute starts no more than 120 seconds before actual issue. Preserve the source-minute uncertainty interval and retrieval time. Expiry is actual issue plus 168 elapsed hours, expected in the 16 October 2026 regular session, 09:30–16:00 EDT (13:30–20:00 UTC). Resolve using the nearest legitimate retained source-timed indicative observation for the same common share and USD currency in that regular session; earlier observation wins an equal-distance tie. The predeclared permitted sources are StockAnalysis’s CBOE-attributed display, Yahoo Finance’s exchange-attributed quote, or the public Nasdaq or NYSE quote. Provider or price-convention changes among these are allowed only when the actual provider, convention, observation precision, retrieval time and signed source-minus-deadline offset are disclosed. A source-timed displayed last price or explicitly indicative share-price estimate is eligible; it is not a promised execution. An explicitly labeled source-timed bar observation is also eligible if its source field, full interval and price convention are retained; it is a bar observation, not an execution at the deadline. Provider and convention changes are predeclared and must be disclosed. No undated daily figure, unstamped current widget or extended-session substitute is allowed. If no legitimate comparable dated endpoint is retained, mark UNVERIFIABLE. BULLISH is HIT only when P1>P0; flat or the opposite sign is MISS. The inclusive ±2% scenario band is separate and never changes directional scoring. Fees, spreads, taxes, financing and dividends are excluded. Publication never restarts the frozen clock. Frozen issue: 2026-10-09T17:25:42.687Z; exact expiry: 2026-10-16T17:25:42.687Z; reference: USD 435.53 per share, source minute 2026-10-09T17:24:00.000Z.", "issueUTC": "2026-10-09T17:25:42.687Z", "expiryUTC": "2026-10-16T17:25:42.687Z" }, "analysis": { "mechanism": "We lean modestly bullish on HUM over one week. Better Medicare ratings remove a specific obstacle to future income. We test further repricing from a fresh reference, while keeping the large opening jump, intraday retreat and delayed cash benefit in view.", "impact": "We start from the competing explanations: further recognition of a repaired earnings path, complete pricing of the news, or a fade after a very large opening gap. The company-specific ratings and official bonus timetable support the first; unchanged current-year guidance, the one-time element and observed retreat support the others. Our 52/30/18 judgment weighs all of them. We did not fit likelihood ratios, infer a posterior from the 49 bars, or borrow OTR’s historical hit rate. This is an explicit subjective estimate with no calibrated confidence interval. A fresh price break or new issuer information requires review before issue, rather than a mechanical copy of this draft.", "key_points": [ "Humana says 95% of its Medicare Advantage members are in contracts rated four stars or better for 2027, with 18 such contracts, 11 more than the previous year. Its new filing says the result exceeds its stated top-quartile goal, defined by the company as Stars revenue per member per month 10% above its peer-group median. We connect that company-specific improvement to the official payment timetable: the ratings enter the next enrollment window, but affect quality bonuses in 2028. Our one-week idea is that reduced uncertainty about a major future-income obstacle can support further valuation changes as investors digest the filing and enrollment starts on 15 October. We are not predicting bonus cash arriving this week or claiming early enrollment results already exist. [Humana](https://news.humana.com/press-room/press-releases/2026/humana-announces-improved-cms-star-ratings-with-95-percent-of) [Company filing](https://www.sec.gov/Archives/edgar/data/49071/000004907126000057/hum-20261009.htm) [CMS timetable](https://www.cms.gov/newsroom/fact-sheets/2027-medicare-advantage-part-d-star-ratings)", "We computed 49 completed daily bars, from 31 July through 8 October. HUM gained 6.39% across those closes and 1.96% over the last five sessions; the 14-session average true range was $15.18. In a separate 9 October research observation at 12:49 EDT, the CBOE-attributed StockAnalysis display was $435.10. The reported opening was $450.49 against a $387.12 previous close: a 16.37% opening gap. The research price was 12.39% above that close, but 3.42% below the open and 4.69% below the $456.50 day high. About three quarters of the opening gain remained. The retreat is real counterevidence to effortless momentum. We do not reconstruct the path between observations or use today’s unfinished row as a completed daily bar. This research quote is not our frozen reference. [Daily table](https://stockanalysis.com/stocks/hum/history/) [Current source](https://stockanalysis.com/stocks/hum/)", "The largest objection is price: most of the initial gain happened before any OTR call, and the share then fell from its opening level. A large event can finish repricing immediately. The filing also says some bonus-year outperformance will be one-time and may fund one-time investment and shareholder returns. It reaffirms 2026 adjusted EPS of at least $9 rather than raising it. The company’s normalized bonus comparison is not an actual 2028 revenue forecast; membership, contract mix, risk scores and payment conditions can change. We therefore reject both “95% of members means 95% earnings growth” and treating the whole future benefit as recurring. Next week’s enrollment opening is a public milestone, not a promised new earnings announcement. [Filing and limitations](https://www.sec.gov/Archives/edgar/data/49071/000004907126000057/hum-20261009.htm)" ], "invalidation": "Before issue, a renewed break below the observed $428.45 session low would require us to reconsider whether buyers are retaining the new rating information. After issue, continued prices below that level or a verified adverse change to the ratings or earnings explanation would weaken the bullish reasoning. Recovery above the $450.49 opening would support the price side, but neither price test proves the business cause. We also weaken the view if enrollment disclosures or an issuer update contradict the assumed benefit. These are review conditions, not stop orders. They cannot change a frozen reference, probabilities, deadline or outcome rule. The one-week outcome remains a same-instrument source-timed price test.", "directional_takeaway": "BULLISH, 168H", "named_assets": [ { "name": "Humana Inc. common stock", "ticker": "HUM", "symbol": "HUM", "direction": "BULLISH", "currency": "USD", "venue": "NYSE-listed / CBOE-attributed StockAnalysis last-price display", "price_unit": "USD per common share" } ] }, "expanded_sections": [ { "title": "What changed?", "text": "Humana says 95% of its Medicare Advantage members are in contracts rated four stars or better for 2027, with 18 such contracts, 11 more than the previous year. Its new filing says the result exceeds its stated top-quartile goal, defined by the company as Stars revenue per member per month 10% above its peer-group median. We connect that company-specific improvement to the official payment timetable: the ratings enter the next enrollment window, but affect quality bonuses in 2028. Our one-week idea is that reduced uncertainty about a major future-income obstacle can support further valuation changes as investors digest the filing and enrollment starts on 15 October. We are not predicting bonus cash arriving this week or claiming early enrollment results already exist. [Humana](https://news.humana.com/press-room/press-releases/2026/humana-announces-improved-cms-star-ratings-with-95-percent-of) [Company filing](https://www.sec.gov/Archives/edgar/data/49071/000004907126000057/hum-20261009.htm) [CMS timetable](https://www.cms.gov/newsroom/fact-sheets/2027-medicare-advantage-part-d-star-ratings)" }, { "title": "Behavioural fingerprint", "text": "We computed 49 completed daily bars, from 31 July through 8 October. HUM gained 6.39% across those closes and 1.96% over the last five sessions; the 14-session average true range was $15.18. In a separate 9 October research observation at 12:49 EDT, the CBOE-attributed StockAnalysis display was $435.10. The reported opening was $450.49 against a $387.12 previous close: a 16.37% opening gap. The research price was 12.39% above that close, but 3.42% below the open and 4.69% below the $456.50 day high. About three quarters of the opening gain remained. The retreat is real counterevidence to effortless momentum. We do not reconstruct the path between observations or use today’s unfinished row as a completed daily bar. This research quote is not our frozen reference. [Daily table](https://stockanalysis.com/stocks/hum/history/) [Current source](https://stockanalysis.com/stocks/hum/)" }, { "title": "Historical comparables", "text": "The 48 completed daily returns split 25 rises and 23 falls, with 23 sign reversals across 47 adjacent pairs. Nine non-overlapping Friday-to-Friday close intervals split six rises and three falls; at a ±2% band they split four bullish, three bearish and two neutral. Their median return was +1.76%. These are small, same-regime observations, not nine independent copies of today’s event. Only two completed opening gaps exceeded 2%: one faded 4.04% from open to close, while the other gained another 2.11%. The largest was only 3.41%, far smaller than today’s 16.37% gap. We found no valid gap-sized analogue in this bounded sample. Close-to-close history also differs from our intraday reference. It frames the uncertainty without manufacturing a success rate for this call. [Numerical history](https://stockanalysis.com/stocks/hum/history/)\n\nFinal reference check: the Oct 9, 2026, 1:24 PM EDT display was USD 435.53, +0.10% versus the earlier research observation. The move was reviewed before issue; the direction and subjective scenario weights remain unchanged. This source-minute display is indicative, not a verified execution." }, { "title": "Evidence graph", "text": "OTR Database Data first connected the new CMS release with different insurer price reactions and warned that national ratings alone cannot justify a company call. We added Humana’s named-contract disclosure, its SEC explanation and our own price calculations. The connection is: company contract improvement → less uncertainty about future bonus eligibility → possible reassessment of future earnings → a testable share-price view this week. The issuer release and SEC filing are one corporate source cluster. CMS is the rule-setter, but these sources share the same underlying rating event, so we do not multiply them as independent votes. The market feed is a separate measurement of reaction, not proof of why investors traded. No national average is substituted for Humana’s exposure. [Issuer contract list](https://news.humana.com/press-room/press-releases/2026/humana-announces-improved-cms-star-ratings-with-95-percent-of) [Official rule and timing](https://www.cms.gov/newsroom/fact-sheets/2027-medicare-advantage-part-d-star-ratings)" }, { "title": "Opposing evidence", "text": "The largest objection is price: most of the initial gain happened before any OTR call, and the share then fell from its opening level. A large event can finish repricing immediately. The filing also says some bonus-year outperformance will be one-time and may fund one-time investment and shareholder returns. It reaffirms 2026 adjusted EPS of at least $9 rather than raising it. The company’s normalized bonus comparison is not an actual 2028 revenue forecast; membership, contract mix, risk scores and payment conditions can change. We therefore reject both “95% of members means 95% earnings growth” and treating the whole future benefit as recurring. Next week’s enrollment opening is a public milestone, not a promised new earnings announcement. [Filing and limitations](https://www.sec.gov/Archives/edgar/data/49071/000004907126000057/hum-20261009.htm)" }, { "title": "Invalidation", "text": "Before issue, a renewed break below the observed $428.45 session low would require us to reconsider whether buyers are retaining the new rating information. After issue, continued prices below that level or a verified adverse change to the ratings or earnings explanation would weaken the bullish reasoning. Recovery above the $450.49 opening would support the price side, but neither price test proves the business cause. We also weaken the view if enrollment disclosures or an issuer update contradict the assumed benefit. These are review conditions, not stop orders. They cannot change a frozen reference, probabilities, deadline or outcome rule. The one-week outcome remains a same-instrument source-timed price test." }, { "title": "Bottom line", "text": "We lean BULLISH over 168 elapsed hours, with a subjective, UNCALIBRATED split of 52% bullish, 30% bearish and 18% neutral around an inclusive ±2% return band. The company-specific repair supports the view; the large prior jump, intraday fade and distant cash benefit keep it modest. The call concerns further repricing after the frozen reference, not credit for the opening gap. This is research, not a promise of profit or a personalized investment recommendation. A valid higher matching endpoint is a directional HIT; equal or lower is a MISS. Missing evidence remains UNVERIFIABLE. The reference and deadline below were frozen once after final quote review." } ], "accordion_sections": [ { "title": "How likely is this call? · Three frameworks", "text": "52% bullish / 30% bearish / 18% neutral; subjective UNCALIBRATED; inclusive ±2% band; 168 elapsed hours. Probabilities are subjective and uncalibrated.", "nested_sections": [ { "title": "Bayesian · what changed the estimate?", "text": "We start from the competing explanations: further recognition of a repaired earnings path, complete pricing of the news, or a fade after a very large opening gap. The company-specific ratings and official bonus timetable support the first; unchanged current-year guidance, the one-time element and observed retreat support the others. Our 52/30/18 judgment weighs all of them. We did not fit likelihood ratios, infer a posterior from the 49 bars, or borrow OTR’s historical hit rate. This is an explicit subjective estimate with no calibrated confidence interval. A fresh price break or new issuer information requires review before issue, rather than a mechanical copy of this draft." }, { "title": "de Finetti · are the comparisons fair?", "text": "The sample and sources are dependent. Friday-to-Friday periods avoid overlapping holding intervals but share one short market regime; rolling seven-day windows overlap and cannot count as independent trials. Only two modest historical gaps were found, neither near today’s size. Humana, its filing and syndicated headlines are one corporate origin, while CMS is the common event behind the story. Related insurers are not extra independent HUM experiments. No same-instrument, same-horizon verified OTR outcome was found in the 397-card novelty screen. The overall ledger score supplies no HUM probability." }, { "title": "Kolmogorov · do the scenarios add up?", "text": "52+30+18=100. For R=(P1/P0−1)×100 over 168 elapsed hours, bullish means R>+2%; bearish means R<−2%; neutral means −2%≤R≤+2%. These are mutually exclusive and exhaustive when a valid matching endpoint exists. A missing or mismatched quote is UNVERIFIABLE, never neutral. The separate BULLISH direction scores HIT only for P1>P0 and MISS for P1≤P0. Thus a small rise may be both a neutral-band outcome and a directional HIT. Adding to 100 does not establish calibration or tradable profit." } ] }, { "title": "Model audit", "text": "Subjective research judgment. No fitted posterior, matched event backtest or held-out calibrator. Preserve both original and any documented learning-adjusted estimates before issue." }, { "title": "Raw data provenance", "text": "49 completed provider daily rows, dated CMS release and company disclosures, plus separate CBOE-attributed source-dated current display. Minute precision remains visible. Private corpus discovery is labelled OTR Database Data." }, { "title": "Resolution ledger", "text": "FROZEN CONTRACT: Humana Inc. common stock, HUM, USD per share. Entry uses the main StockAnalysis real-time price display attributed to CBOE, an indicative provider display rather than a verified primary-exchange execution or user fill. Freeze only in the regular US equity session when the displayed full-date source minute starts no more than 120 seconds before actual issue. Preserve the source-minute uncertainty interval and retrieval time. Expiry is actual issue plus 168 elapsed hours, expected in the 16 October 2026 regular session, 09:30–16:00 EDT (13:30–20:00 UTC). Resolve using the nearest legitimate retained source-timed indicative observation for the same common share and USD currency in that regular session; earlier observation wins an equal-distance tie. The predeclared permitted sources are StockAnalysis’s CBOE-attributed display, Yahoo Finance’s exchange-attributed quote, or the public Nasdaq or NYSE quote. Provider or price-convention changes among these are allowed only when the actual provider, convention, observation precision, retrieval time and signed source-minus-deadline offset are disclosed. A source-timed displayed last price or explicitly indicative share-price estimate is eligible; it is not a promised execution. An explicitly labeled source-timed bar observation is also eligible if its source field, full interval and price convention are retained; it is a bar observation, not an execution at the deadline. Provider and convention changes are predeclared and must be disclosed. No undated daily figure, unstamped current widget or extended-session substitute is allowed. If no legitimate comparable dated endpoint is retained, mark UNVERIFIABLE. BULLISH is HIT only when P1>P0; flat or the opposite sign is MISS. The inclusive ±2% scenario band is separate and never changes directional scoring. Fees, spreads, taxes, financing and dividends are excluded. Publication never restarts the frozen clock. Frozen issue: 2026-10-09T17:25:42.687Z; exact expiry: 2026-10-16T17:25:42.687Z; reference: USD 435.53 per share, source minute 2026-10-09T17:24:00.000Z." } ], "resolution_rule": "FROZEN CONTRACT: Humana Inc. common stock, HUM, USD per share. Entry uses the main StockAnalysis real-time price display attributed to CBOE, an indicative provider display rather than a verified primary-exchange execution or user fill. Freeze only in the regular US equity session when the displayed full-date source minute starts no more than 120 seconds before actual issue. Preserve the source-minute uncertainty interval and retrieval time. Expiry is actual issue plus 168 elapsed hours, expected in the 16 October 2026 regular session, 09:30–16:00 EDT (13:30–20:00 UTC). Resolve using the nearest legitimate retained source-timed indicative observation for the same common share and USD currency in that regular session; earlier observation wins an equal-distance tie. The predeclared permitted sources are StockAnalysis’s CBOE-attributed display, Yahoo Finance’s exchange-attributed quote, or the public Nasdaq or NYSE quote. Provider or price-convention changes among these are allowed only when the actual provider, convention, observation precision, retrieval time and signed source-minus-deadline offset are disclosed. A source-timed displayed last price or explicitly indicative share-price estimate is eligible; it is not a promised execution. An explicitly labeled source-timed bar observation is also eligible if its source field, full interval and price convention are retained; it is a bar observation, not an execution at the deadline. Provider and convention changes are predeclared and must be disclosed. No undated daily figure, unstamped current widget or extended-session substitute is allowed. If no legitimate comparable dated endpoint is retained, mark UNVERIFIABLE. BULLISH is HIT only when P1>P0; flat or the opposite sign is MISS. The inclusive ±2% scenario band is separate and never changes directional scoring. Fees, spreads, taxes, financing and dividends are excluded. Publication never restarts the frozen clock. Frozen issue: 2026-10-09T17:25:42.687Z; exact expiry: 2026-10-16T17:25:42.687Z; reference: USD 435.53 per share, source minute 2026-10-09T17:24:00.000Z.", "resolution_ledger": { "status": "PENDING", "result": null, "issue_utc": "2026-10-09T17:25:42.687Z", "expiry_utc": "2026-10-16T17:25:42.687Z", "price1": 435.53, "price2": null, "resolution_rule": "FROZEN CONTRACT: Humana Inc. common stock, HUM, USD per share. Entry uses the main StockAnalysis real-time price display attributed to CBOE, an indicative provider display rather than a verified primary-exchange execution or user fill. Freeze only in the regular US equity session when the displayed full-date source minute starts no more than 120 seconds before actual issue. Preserve the source-minute uncertainty interval and retrieval time. Expiry is actual issue plus 168 elapsed hours, expected in the 16 October 2026 regular session, 09:30–16:00 EDT (13:30–20:00 UTC). Resolve using the nearest legitimate retained source-timed indicative observation for the same common share and USD currency in that regular session; earlier observation wins an equal-distance tie. The predeclared permitted sources are StockAnalysis’s CBOE-attributed display, Yahoo Finance’s exchange-attributed quote, or the public Nasdaq or NYSE quote. Provider or price-convention changes among these are allowed only when the actual provider, convention, observation precision, retrieval time and signed source-minus-deadline offset are disclosed. A source-timed displayed last price or explicitly indicative share-price estimate is eligible; it is not a promised execution. An explicitly labeled source-timed bar observation is also eligible if its source field, full interval and price convention are retained; it is a bar observation, not an execution at the deadline. Provider and convention changes are predeclared and must be disclosed. No undated daily figure, unstamped current widget or extended-session substitute is allowed. If no legitimate comparable dated endpoint is retained, mark UNVERIFIABLE. BULLISH is HIT only when P1>P0; flat or the opposite sign is MISS. The inclusive ±2% scenario band is separate and never changes directional scoring. Fees, spreads, taxes, financing and dividends are excluded. Publication never restarts the frozen clock. Frozen issue: 2026-10-09T17:25:42.687Z; exact expiry: 2026-10-16T17:25:42.687Z; reference: USD 435.53 per share, source minute 2026-10-09T17:24:00.000Z.", "price1_source_clock_utc": "2026-10-09T17:24:00.000Z", "price1_retrieved_at_utc": "2026-10-09T17:25:33.304Z" }, "supplied_reference_quote": { "price": 435.53, "symbol": "HUM", "instrument": "Humana Inc. common stock", "currency": "USD", "unit": "USD per common share", "price_unit": "USD per common share", "venue": "NYSE-listed / CBOE-attributed StockAnalysis last-price display", "source_url": "https://stockanalysis.com/stocks/hum/", "price_type": "PROVIDER_LAST_SALE_DISPLAY", "provider": "StockAnalysis CBOE-attributed display", "source_clock_display": "Oct 9, 2026, 1:24 PM EDT", "source_clock_utc": "2026-10-09T17:24:00.000Z", "source_clock_interval_utc": [ "2026-10-09T17:24:00.000Z", "2026-10-09T17:24:59.999Z" ], "source_clock_precision_seconds": 60, "source_clock_basis": "Displayed EDT provider price-update minute; converted using America/New_York. Minute start is a conservative age proxy, not an exact trade time.", "retrieved_at_utc": "2026-10-09T17:25:33.304Z", "captured_at_utc": "2026-10-09T17:25:33.304Z", "capture_started_at_utc": "2026-10-09T17:25:24.867Z", "raw_receipt_sha256": "ae4ecf2444bf90a412579fab682a0cc156df38d90b7a02ddbc1d9e1f9281417b", "observation_time_verified": true, "executed_trade_verified": false, "not_yet_frozen": false, "conservative_age_at_capture_seconds": 93.304, "as_of_utc": "2026-10-09T17:24:00.000Z", "quote_age_at_issue_seconds": 102.687992 }, "current_price_display": "USD 435.53", "change_24h_display": "", "blank_change_24h": true, "novelty_review": { "status": "ALL_397_KEYWORD_SCREEN_NO_HUM_MATCH", "new_connection": "Company contract ratings repair joined to the 2028 payment delay, the one-time benefit caveat and the measured opening-gap fade; exact issuer exposure added beyond national CMS data." }, "review_status": "OPPOSING_REVIEW_PASSED_WITH_LIMITS", "source_batch": "signals-six-desk-20261009-1644", "card_scope": "current_research_signal", "research_cutoff_utc": "2026-10-09T17:14:30Z", "scope_note": "Issued research call with immutable reference and expiry. Future outcome is pending.", "public_expanded_text": "What changed?\nHumana says 95% of its Medicare Advantage members are in contracts rated four stars or better for 2027, with 18 such contracts, 11 more than the previous year. Its new filing says the result exceeds its stated top-quartile goal, defined by the company as Stars revenue per member per month 10% above its peer-group median. We connect that company-specific improvement to the official payment timetable: the ratings enter the next enrollment window, but affect quality bonuses in 2028. Our one-week idea is that reduced uncertainty about a major future-income obstacle can support further valuation changes as investors digest the filing and enrollment starts on 15 October. We are not predicting bonus cash arriving this week or claiming early enrollment results already exist. [Humana](https://news.humana.com/press-room/press-releases/2026/humana-announces-improved-cms-star-ratings-with-95-percent-of) [Company filing](https://www.sec.gov/Archives/edgar/data/49071/000004907126000057/hum-20261009.htm) [CMS timetable](https://www.cms.gov/newsroom/fact-sheets/2027-medicare-advantage-part-d-star-ratings)\n\nBehavioural fingerprint\nWe computed 49 completed daily bars, from 31 July through 8 October. HUM gained 6.39% across those closes and 1.96% over the last five sessions; the 14-session average true range was $15.18. In a separate 9 October research observation at 12:49 EDT, the CBOE-attributed StockAnalysis display was $435.10. The reported opening was $450.49 against a $387.12 previous close: a 16.37% opening gap. The research price was 12.39% above that close, but 3.42% below the open and 4.69% below the $456.50 day high. About three quarters of the opening gain remained. The retreat is real counterevidence to effortless momentum. We do not reconstruct the path between observations or use today’s unfinished row as a completed daily bar. This research quote is not our frozen reference. [Daily table](https://stockanalysis.com/stocks/hum/history/) [Current source](https://stockanalysis.com/stocks/hum/)\n\nHistorical comparables\nThe 48 completed daily returns split 25 rises and 23 falls, with 23 sign reversals across 47 adjacent pairs. Nine non-overlapping Friday-to-Friday close intervals split six rises and three falls; at a ±2% band they split four bullish, three bearish and two neutral. Their median return was +1.76%. These are small, same-regime observations, not nine independent copies of today’s event. Only two completed opening gaps exceeded 2%: one faded 4.04% from open to close, while the other gained another 2.11%. The largest was only 3.41%, far smaller than today’s 16.37% gap. We found no valid gap-sized analogue in this bounded sample. Close-to-close history also differs from our intraday reference. It frames the uncertainty without manufacturing a success rate for this call. [Numerical history](https://stockanalysis.com/stocks/hum/history/)\n\nFinal reference check: the Oct 9, 2026, 1:24 PM EDT display was USD 435.53, +0.10% versus the earlier research observation. The move was reviewed before issue; the direction and subjective scenario weights remain unchanged. This source-minute display is indicative, not a verified execution.\n\nEvidence graph\nOTR Database Data first connected the new CMS release with different insurer price reactions and warned that national ratings alone cannot justify a company call. We added Humana’s named-contract disclosure, its SEC explanation and our own price calculations. The connection is: company contract improvement → less uncertainty about future bonus eligibility → possible reassessment of future earnings → a testable share-price view this week. The issuer release and SEC filing are one corporate source cluster. CMS is the rule-setter, but these sources share the same underlying rating event, so we do not multiply them as independent votes. The market feed is a separate measurement of reaction, not proof of why investors traded. No national average is substituted for Humana’s exposure. [Issuer contract list](https://news.humana.com/press-room/press-releases/2026/humana-announces-improved-cms-star-ratings-with-95-percent-of) [Official rule and timing](https://www.cms.gov/newsroom/fact-sheets/2027-medicare-advantage-part-d-star-ratings)\n\nOpposing evidence\nThe largest objection is price: most of the initial gain happened before any OTR call, and the share then fell from its opening level. A large event can finish repricing immediately. The filing also says some bonus-year outperformance will be one-time and may fund one-time investment and shareholder returns. It reaffirms 2026 adjusted EPS of at least $9 rather than raising it. The company’s normalized bonus comparison is not an actual 2028 revenue forecast; membership, contract mix, risk scores and payment conditions can change. We therefore reject both “95% of members means 95% earnings growth” and treating the whole future benefit as recurring. Next week’s enrollment opening is a public milestone, not a promised new earnings announcement. [Filing and limitations](https://www.sec.gov/Archives/edgar/data/49071/000004907126000057/hum-20261009.htm)\n\nInvalidation\nBefore issue, a renewed break below the observed $428.45 session low would require us to reconsider whether buyers are retaining the new rating information. After issue, continued prices below that level or a verified adverse change to the ratings or earnings explanation would weaken the bullish reasoning. Recovery above the $450.49 opening would support the price side, but neither price test proves the business cause. We also weaken the view if enrollment disclosures or an issuer update contradict the assumed benefit. These are review conditions, not stop orders. They cannot change a frozen reference, probabilities, deadline or outcome rule. The one-week outcome remains a same-instrument source-timed price test.\n\nBottom line\nWe lean BULLISH over 168 elapsed hours, with a subjective, UNCALIBRATED split of 52% bullish, 30% bearish and 18% neutral around an inclusive ±2% return band. The company-specific repair supports the view; the large prior jump, intraday fade and distant cash benefit keep it modest. The call concerns further repricing after the frozen reference, not credit for the opening gap. This is research, not a promise of profit or a personalized investment recommendation. A valid higher matching endpoint is a directional HIT; equal or lower is a MISS. Missing evidence remains UNVERIFIABLE. The reference and deadline below were frozen once after final quote review.", "history_coverage": { "completed_daily_rows": 49, "from": "2026-07-31", "through": "2026-10-08", "source_pages": 1, "timeframes_obtained": [ "daily OHLCV" ], "no_imputation": true, "same_venue_as_reference": false, "note": "S&P Global daily table for descriptive history; live reference is CBOE-attributed display. Today incomplete and excluded." }, "review": { "status": "OPPOSING_REVIEW_PASSED_WITH_LIMITS", "facts_and_prices_fully_verified": false, "reference_quote_verified_with_limits": true, "research_facts_reviewed_at_utc": "2026-10-09T16:54:11Z", "research_facts_verified": true, "corporate_action_scope": "Latest declared dividend record and payment dates are after expected168hendpoint; no total-return or comprehensive corporate-action claim.", "reference_quote_verified_at_utc": "2026-10-09T17:25:42.687Z", "executed_trade_verified": false }, "formation_chain": [ { "step": "Observed change", "text": "Humana says 95% of its Medicare Advantage members are in contracts rated four stars or better for 2027, with 18 such contracts, 11 more than the previous year. Its new filing says the result exceeds its stated top-quartile goal, defined by the company as Stars revenue per member per month 10% above its peer-group median. We connect that company-specific improvement to the official payment timetable: the ratings enter the next enrollment window, but affect quality bonuses in 2028. Our one-week idea is that reduced uncertainty about a major future-income obstacle can support further valuation changes as investors digest the filing and enrollment starts on 15 October. We are not predicting bonus cash arriving this week or claiming early enrollment results already exist. [Humana](https://news.humana.com/press-room/press-releases/2026/humana-announces-improved-cms-star-ratings-with-95-percent-of) [Company filing](https://www.sec.gov/Archives/edgar/data/49071/000004907126000057/hum-20261009.htm) [CMS timetable](https://www.cms.gov/newsroom/fact-sheets/2027-medicare-advantage-part-d-star-ratings)" }, { "step": "Transmission", "text": "OTR Database Data first connected the new CMS release with different insurer price reactions and warned that national ratings alone cannot justify a company call. We added Humana’s named-contract disclosure, its SEC explanation and our own price calculations. The connection is: company contract improvement → less uncertainty about future bonus eligibility → possible reassessment of future earnings → a testable share-price view this week. The issuer release and SEC filing are one corporate source cluster. CMS is the rule-setter, but these sources share the same underlying rating event, so we do not multiply them as independent votes. The market feed is a separate measurement of reaction, not proof of why investors traded. No national average is substituted for Humana’s exposure. [Issuer contract list](https://news.humana.com/press-room/press-releases/2026/humana-announces-improved-cms-star-ratings-with-95-percent-of) [Official rule and timing](https://www.cms.gov/newsroom/fact-sheets/2027-medicare-advantage-part-d-star-ratings)" }, { "step": "Already reflected", "text": "We computed 49 completed daily bars, from 31 July through 8 October. HUM gained 6.39% across those closes and 1.96% over the last five sessions; the 14-session average true range was $15.18. In a separate 9 October research observation at 12:49 EDT, the CBOE-attributed StockAnalysis display was $435.10. The reported opening was $450.49 against a $387.12 previous close: a 16.37% opening gap. The research price was 12.39% above that close, but 3.42% below the open and 4.69% below the $456.50 day high. About three quarters of the opening gain remained. The retreat is real counterevidence to effortless momentum. We do not reconstruct the path between observations or use today’s unfinished row as a completed daily bar. This research quote is not our frozen reference. [Daily table](https://stockanalysis.com/stocks/hum/history/) [Current source](https://stockanalysis.com/stocks/hum/)" }, { "step": "Opposition", "text": "The largest objection is price: most of the initial gain happened before any OTR call, and the share then fell from its opening level. A large event can finish repricing immediately. The filing also says some bonus-year outperformance will be one-time and may fund one-time investment and shareholder returns. It reaffirms 2026 adjusted EPS of at least $9 rather than raising it. The company’s normalized bonus comparison is not an actual 2028 revenue forecast; membership, contract mix, risk scores and payment conditions can change. We therefore reject both “95% of members means 95% earnings growth” and treating the whole future benefit as recurring. Next week’s enrollment opening is a public milestone, not a promised new earnings announcement. [Filing and limitations](https://www.sec.gov/Archives/edgar/data/49071/000004907126000057/hum-20261009.htm)" }, { "step": "Timeboxed judgment", "text": "We lean BULLISH over 168 elapsed hours, with a subjective, UNCALIBRATED split of 52% bullish, 30% bearish and 18% neutral around an inclusive ±2% return band. The company-specific repair supports the view; the large prior jump, intraday fade and distant cash benefit keep it modest. The call concerns further repricing after the frozen reference, not credit for the opening gap. This is research, not a promise of profit or a personalized investment recommendation. A valid higher matching endpoint is a directional HIT; equal or lower is a MISS. Missing evidence remains UNVERIFIABLE. The reference and deadline below were frozen once after final quote review." } ], "forecast_clock_basis": "ACTUAL_RESEARCH_ISSUE_SEPARATE_FROM_NATIVE_PUBLICATION", "forecast_clock_label": "Issued 2026-10-09T17:25:42.687Z; expires 2026-10-16T17:25:42.687Z", "evidence_cutoff_utc": "2026-10-09T17:14:30Z", "card_evidence_cutoff_utc": "2026-10-09T17:14:30Z", "fact_review_state": "RESEARCH_PASSED_REFERENCE_VERIFIED", "outcome_contract": { "directional_rule": "sign_only", "endpoint_selection": "nearest_legitimate_source_timed_indicative_observation", "provider_change_policy": "allow_if_predeclared_and_disclosed", "allowed_providers": [ "StockAnalysis CBOE-attributed display", "Yahoo Finance exchange-attributed quote", "Nasdaq public quote", "NYSE public quote" ], "same_instrument_and_currency_required": true, "missing_endpoint": "UNVERIFIABLE", "neutral_band_affects_directional_result": false, "regular_session_only": true, "tie_break": "earlier_observation", "price_conventions_allowed": [ "source-timed displayed last price", "explicitly indicative share-price estimate" ], "disclose_actual_endpoint_provider_and_convention": true, "eligible_observation_kinds": [ "source_timed_quote", "explicitly_labeled_timestamped_bar" ], "timestamped_bar_requires_source_field_interval_and_label": true, "no_undated_daily_or_current_widget_substitute": true, "allowed_price_conventions": [ "PROVIDER_LAST_SALE_DISPLAY", "EXCHANGE_ATTRIBUTED_LAST_PRICE", "EXPLICITLY_INDICATIVE_SHARE_PRICE", "TIMESTAMPED_BAR_CLOSE" ], "convention_change_policy": "allow_if_predeclared_and_disclosed", "convention_change_disclosure_required": true, "rule": "FROZEN CONTRACT: Humana Inc. common stock, HUM, USD per share. Entry uses the main StockAnalysis real-time price display attributed to CBOE, an indicative provider display rather than a verified primary-exchange execution or user fill. Freeze only in the regular US equity session when the displayed full-date source minute starts no more than 120 seconds before actual issue. Preserve the source-minute uncertainty interval and retrieval time. Expiry is actual issue plus 168 elapsed hours, expected in the 16 October 2026 regular session, 09:30–16:00 EDT (13:30–20:00 UTC). Resolve using the nearest legitimate retained source-timed indicative observation for the same common share and USD currency in that regular session; earlier observation wins an equal-distance tie. The predeclared permitted sources are StockAnalysis’s CBOE-attributed display, Yahoo Finance’s exchange-attributed quote, or the public Nasdaq or NYSE quote. Provider or price-convention changes among these are allowed only when the actual provider, convention, observation precision, retrieval time and signed source-minus-deadline offset are disclosed. A source-timed displayed last price or explicitly indicative share-price estimate is eligible; it is not a promised execution. An explicitly labeled source-timed bar observation is also eligible if its source field, full interval and price convention are retained; it is a bar observation, not an execution at the deadline. Provider and convention changes are predeclared and must be disclosed. No undated daily figure, unstamped current widget or extended-session substitute is allowed. If no legitimate comparable dated endpoint is retained, mark UNVERIFIABLE. BULLISH is HIT only when P1>P0; flat or the opposite sign is MISS. The inclusive ±2% scenario band is separate and never changes directional scoring. Fees, spreads, taxes, financing and dividends are excluded. Publication never restarts the frozen clock. Frozen issue: 2026-10-09T17:25:42.687Z; exact expiry: 2026-10-16T17:25:42.687Z; reference: USD 435.53 per share, source minute 2026-10-09T17:24:00.000Z.", "disclosure_required": true, "provider_change_disclosure_required": true }, "forecast_issued_at_utc": "2026-10-09T17:25:42.687Z", "issued_at_utc": "2026-10-09T17:25:42.687Z", "frozen_at_utc": "2026-10-09T17:25:42.687Z", "final_reference_context": "Final reference check: the Oct 9, 2026, 1:24 PM EDT display was USD 435.53, +0.10% versus the earlier research observation. The move was reviewed before issue; the direction and subjective scenario weights remain unchanged. This source-minute display is indicative, not a verified execution.", "probability_framework_sections": [ { "title": "Bayesian · what changed the estimate?", "text": "We start from the competing explanations: further recognition of a repaired earnings path, complete pricing of the news, or a fade after a very large opening gap. The company-specific ratings and official bonus timetable support the first; unchanged current-year guidance, the one-time element and observed retreat support the others. Our 52/30/18 judgment weighs all of them. We did not fit likelihood ratios, infer a posterior from the 49 bars, or borrow OTR’s historical hit rate. This is an explicit subjective estimate with no calibrated confidence interval. A fresh price break or new issuer information requires review before issue, rather than a mechanical copy of this draft." }, { "title": "de Finetti · are the comparisons fair?", "text": "The sample and sources are dependent. Friday-to-Friday periods avoid overlapping holding intervals but share one short market regime; rolling seven-day windows overlap and cannot count as independent trials. Only two modest historical gaps were found, neither near today’s size. Humana, its filing and syndicated headlines are one corporate origin, while CMS is the common event behind the story. Related insurers are not extra independent HUM experiments. No same-instrument, same-horizon verified OTR outcome was found in the 397-card novelty screen. The overall ledger score supplies no HUM probability." }, { "title": "Kolmogorov · do the scenarios add up?", "text": "52+30+18=100. For R=(P1/P0−1)×100 over 168 elapsed hours, bullish means R>+2%; bearish means R<−2%; neutral means −2%≤R≤+2%. These are mutually exclusive and exhaustive when a valid matching endpoint exists. A missing or mismatched quote is UNVERIFIABLE, never neutral. The separate BULLISH direction scores HIT only for P1>P0 and MISS for P1≤P0. Thus a small rise may be both a neutral-band outcome and a directional HIT. Adding to 100 does not establish calibration or tradable profit." } ], "research_prepared_at_utc": "2026-10-09T16:53:23Z", "release_id": "OTR-SIGNALS-20261009T171430Z-R1" }, { "schema": "OTR-SIGNAL-CARD-1", "id": "INV-20261009-PEP-MARGIN-RESET-168H", "publication_status": "READY", "status": "PENDING", "primary_category": "investments", "categories": [ "investments" ], "title": "PepsiCo’s sales improve while its earnings outlook loses support", "summary": "We lean BEARISH for 168 elapsed hours, from the frozen entry reference:26% bullish,52% bearish,22% neutral around an inclusive ±1.5% return band. These are subjective UNCALIBRATED judgments. We test further repricing of weaker profit growth, not a guaranteed collapse in sales. The initial earnings move cannot count as our result. A valid lower matching endpoint is a directional HIT; flat or higher is a MISS.", "signal_claim": "We lean BEARISH for 168 elapsed hours, from the frozen entry reference:26% bullish,52% bearish,22% neutral around an inclusive ±1.5% return band. These are subjective UNCALIBRATED judgments. We test further repricing of weaker profit growth, not a guaranteed collapse in sales. The initial earnings move cannot count as our result. A valid lower matching endpoint is a directional HIT; flat or higher is a MISS.", "thesis": "We lean BEARISH for 168 elapsed hours, from the frozen entry reference:26% bullish,52% bearish,22% neutral around an inclusive ±1.5% return band. These are subjective UNCALIBRATED judgments. We test further repricing of weaker profit growth, not a guaranteed collapse in sales. The initial earnings move cannot count as our result. A valid lower matching endpoint is a directional HIT; flat or higher is a MISS.", "key_points": [ "PepsiCo lowered its full-year core constant-currency EPS growth expectation to 1–2%, from the low end of 4–6%. This is important because its expected tax rate fell and its currency contribution improved, yet the profit outlook still weakened. Quarterly core margin fell 35 basis points despite revenue growth. Our one-week bearish idea is that investors may put more weight on this weaker conversion of sales to profit after the initial earnings rally. These are company-defined non-GAAP measures, not GAAP EPS. [Primary results and guidance](https://www.sec.gov/Archives/edgar/data/77476/000007747626000050/q320268-kxexhibit991.htm)", "We use 24 completed daily rows from 4 September through 8 October, beginning on the reported ex-dividend date so we do not splice adjusted and raw closes. The share fell 6.75% across the sample; the last five sessions gained 2.18%, driven by the 3.73% earnings-day rise. The 14-session average true range was $2.50. At 13:05 EDT on 9 October, the current display read $126.33,1.57% below the prior $128.34 close and 0.29% below today’s $126.70 open. This is a partial fade, not a complete reversal of yesterday’s jump. [History](https://stockanalysis.com/stocks/pep/history/) [Research display](https://stockanalysis.com/stocks/pep/)", "The bullish case is substantial. Yesterday’s shares rose 3.73% after the release, so investors may be rewarding improving volumes, international growth or a less demanding valuation. Management describes better North American food trends and intends more cost actions. Expected shareholder cash returns remain $8.9 billion, while free-cash-flow conversion guidance is unchanged. Most importantly, much weakness preceded our call. A one-day fade cannot prove the market will reverse its earnings response. [Issuer countercase](https://www.sec.gov/Archives/edgar/data/77476/000007747626000050/q320268-kxexhibit991.htm)" ], "bottom_line": "We lean BEARISH for 168 elapsed hours, from the frozen entry reference:26% bullish,52% bearish,22% neutral around an inclusive ±1.5% return band. These are subjective UNCALIBRATED judgments. We test further repricing of weaker profit growth, not a guaranteed collapse in sales. The initial earnings move cannot count as our result. A valid lower matching endpoint is a directional HIT; flat or higher is a MISS.", "named_assets": [ { "name": "PepsiCo, Inc. common stock", "ticker": "PEP", "symbol": "PEP", "direction": "BEARISH", "currency": "USD", "venue": "Nasdaq-listed / CBOE-attributed StockAnalysis last-price display", "price_unit": "USD per common share" } ], "directional_takeaway": "BEARISH, 168 H", "prediction_activation": "ISSUED_FROZEN", "scoring_eligible": true, "entry_status": "FROZEN", "forecast_prepared_at_utc": "2026-10-09T17:25:55.177Z", "publication_timestamp": "2026-10-09T17:25:55.177Z", "native_publication_time_utc": null, "check_time_utc": "2026-10-16T17:25:55.177Z", "check_time_label": "168 elapsed hours after actual issue", "source_labels": [ "OTR Database Data", "Primary company disclosures", "StockAnalysis" ], "sources": [ { "title": "PepsiCo via SEC", "url": "https://www.sec.gov/Archives/edgar/data/77476/000007747626000050/q320268-kxexhibit991.htm", "publisher": "PepsiCo via SEC", "published_at": "2026-10-08", "publication_time_precision": "DATE_ONLY", "retrieved_at_utc": "2026-10-09T17:06:51Z", "cluster_id": "PEP-ISSUER" }, { "title": "StockAnalysis daily history", "url": "https://stockanalysis.com/stocks/pep/history/", "publisher": "StockAnalysis daily history", "published_at": null, "publication_time_precision": null, "retrieved_at_utc": "2026-10-09T17:06:51Z", "cluster_id": "PEP-MARKET" }, { "title": "StockAnalysis current display", "url": "https://stockanalysis.com/stocks/pep/", "publisher": "StockAnalysis current display", "published_at": null, "publication_time_precision": null, "retrieved_at_utc": "2026-10-09T17:06:51Z", "cluster_id": "PEP-MARKET" } ], "source_links": [ { "title": "PepsiCo via SEC", "url": "https://www.sec.gov/Archives/edgar/data/77476/000007747626000050/q320268-kxexhibit991.htm" }, { "title": "StockAnalysis daily history", "url": "https://stockanalysis.com/stocks/pep/history/" }, { "title": "StockAnalysis current display", "url": "https://stockanalysis.com/stocks/pep/" } ], "source_confidence": "Primary disclosures and numerical provider history checked; directional probabilities are subjective and UNCALIBRATED.", "source_gaps": [ "Bounded daily history and isolated intraday research observations only; no event-matched backtest.", "No fitted likelihoods, calibrated probabilities, order flow, borrow-cost or after-cost return estimate.", "Primary source and syndication are not independent confirmations.", "Fresh source-dated reference is frozen; the future endpoint remains pending." ], "probability_model_version": "OTR-SUBJECTIVE-PEP-20261009-1", "probability_input": { "mode": "subjective", "label": "Subjective UNCALIBRATED estimate frozen at 2026-10-09T17:25:55.177Z; directional scoring is separate from the scenario band.", "bullishPercent": 26, "bearishPercent": 52, "neutralPercent": 22, "neutralBandPct": 1.5, "horizonHours": 168, "referencePrice": 126.21, "currency": "USD", "instrument": "PepsiCo, Inc. common stock", "venue": "Nasdaq-listed / CBOE-attributed StockAnalysis last-price display", "entryQuoteMaximumAgeSeconds": 120, "bayesian": "We give the profit-guidance reduction and narrowing core margin more weight than the headline GAAP EPS improvement. More favorable tax and currency assumptions do not prevent the cut. The positive earnings-day reaction, improving volumes and retained cash-return plan materially temper that view. Our 26/52/22 split is a research judgment, not a fitted Bayesian posterior; no numerical likelihood ratios or calibrated interval exist.", "deFinetti": "Four weekly periods share one declining regime. We do not use their four declines to assign 100% odds. There is no event-matched earnings-cut study. Company releases and their SEC or wire copies are one origin. The market records a reaction, not its cause. Other stocks sharing a narrative do not supply independent trials. OTR’s historical hit rate is not this instrument’s prior.", "kolmogorov": "26+52+22=100. For R=(P 1/P 0−1)×100 over 168 elapsed hours, bullish means R>+1.5%, bearish means R<−1.5%, and neutral includes both boundaries between them. The separate BEARISH call is HIT only if P 1

+1.5%, bearish means R<−1.5%, and neutral includes both boundaries between them. The separate BEARISH call is HIT only if P 1

+1.5%, bearish means R<−1.5%, and neutral includes both boundaries between them. The separate BEARISH call is HIT only if P 1

+2%, bearish means R<−2%, and neutral includes both boundaries between them. The separate BEARISH call is HIT only if P 1

+2%, bearish means R<−2%, and neutral includes both boundaries between them. The separate BEARISH call is HIT only if P 1

+2%, bearish means R<−2%, and neutral includes both boundaries between them. The separate BEARISH call is HIT only if P 1

+1.5%, bearish means R<−1.5%, and neutral means −1.5%≤R≤+1.5%. Those outcomes are exhaustive only for a valid matching endpoint. Missing or mismatched evidence is UNVERIFIABLE. The separate BEARISH direction is HIT for P1+1.5%, bearish means R<−1.5%, and neutral means −1.5%≤R≤+1.5%. Those outcomes are exhaustive only for a valid matching endpoint. Missing or mismatched evidence is UNVERIFIABLE. The separate BEARISH direction is HIT for P1+1.5%, bearish means R<−1.5%, and neutral means −1.5%≤R≤+1.5%. Those outcomes are exhaustive only for a valid matching endpoint. Missing or mismatched evidence is UNVERIFIABLE. The separate BEARISH direction is HIT for P1+1.5%, bearish means R<−1.5%, and neutral means −1.5%≤R≤+1.5%. Those outcomes are exhaustive only for a valid matching endpoint. Missing or mismatched evidence is UNVERIFIABLE. The separate BEARISH direction is HIT for P1+1.5%, bearish means R<−1.5%, and neutral means −1.5%≤R≤+1.5%. Those outcomes are exhaustive only for a valid matching endpoint. Missing or mismatched evidence is UNVERIFIABLE. The separate BEARISH direction is HIT for P1